Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy (SMA) is a genetic motor neuron disease that primarily affects the lower motor neurons in the spinal cord, leading to muscle weakness and atrophy. It belongs to the broader category of Motor Neuron Diseases (MND), alongside ALS, but differs in cause, age of onset, and progression pattern. SMA typically begins in infancy or childhood, though adult-onset variants exist.

Overview

SMA is caused by mutations or deletions in the SMN1 gene (Survival Motor Neuron 1), resulting in insufficient production of SMN protein, which is essential for motor neuron survival. Without adequate SMN protein, motor neurons in the spinal cord’s anterior horn degenerate, impairing muscle control. SMA mainly affects proximal muscles of the trunk and limbs (e.g., shoulders, thighs), but does not impair cognition or sensory function.

Types of SMA

1. SMA Type I (Infantile, Werdnig-Hoffmann disease)
   • Onset: within 6 months of birth
   • Symptoms: severe weakness, inability to sit, swallowing and breathing difficulties
   • Prognosis: without treatment, most infants die before age 2 due to respiratory failure
2. SMA Type II (Intermediate)
   • Onset: 6–18 months
   • Symptoms: able to sit but not walk independently, weakness, scoliosis common
   • Prognosis: survival into adolescence or adulthood, often requiring respiratory support
3. SMA Type III (Juvenile, Kugelberg-Welander disease)
   • Onset: after 18 months, usually in childhood/adolescence
   • Symptoms: gradual loss of walking ability, milder weakness
   • Prognosis: near-normal lifespan, but limited mobility
4. SMA Type IV (Adult-onset)
   • Onset: adulthood (typically after age 30)
   • Symptoms: mild weakness, slow progression
   • Prognosis: minimal impact on lifespan

Symptoms

• Muscle weakness and atrophy (legs, hips, shoulders, back)
• Delayed motor development (difficulty rolling, sitting, walking)
• Breathing problems due to weak chest muscles → risk of infections or respiratory failure
• Skeletal deformities (e.g., scoliosis, especially in Types II & III)
• Fasciculations (tiny twitches in tongue or hands)

SMA does not affect intelligence, emotions, or sensory function; patients remain fully conscious.

Causes

• Genetic inheritance: SMA is an autosomal recessive disorder caused by SMN1 mutations. Both parents must carry the defective gene; children then have a 25% chance of developing SMA.
• SMN2 gene influence: SMN2 acts as a backup gene, producing small amounts of functional SMN protein. More SMN2 copies generally mean milder symptoms, explaining differences in severity among types.

Diagnosis

• Genetic testing: confirms SMN1 mutation/deletion (most reliable)
• Electromyography (EMG): detects abnormal muscle/nerve activity
• Clinical observation: evaluates weakness and motor milestones
• Family history: confirms inheritance pattern

Treatment

Recent breakthroughs have transformed SMA care from purely supportive to targeted therapies:

1. Gene therapy
   • Zolgensma (onasemnogene abeparvovec): one-time IV infusion delivering functional SMN1 gene, for patients under 2 years. Dramatically improves motor function but extremely costly (~USD 2 million).
2. Drug therapies
   • Nusinersen (Spinraza): spinal injections boosting SMN2 protein production, requires ongoing dosing.
   • Risdiplam (Evrysdi): oral medication increasing SMN2 protein output, suitable for most age groups.
3. Supportive care
   • Physical therapy: prevents contractures and stiffness
   • Respiratory support: non-invasive ventilation, especially for Types I & II
   • Nutritional management: ensures adequate intake for patients with swallowing difficulties

Prognosis

• Without treatment: Type I has the poorest outlook; Types II & III allow longer survival; Type IV has minimal impact.
• With treatment: New therapies significantly extend lifespan and improve function, especially with early diagnosis. For example, Type I patients treated with Zolgensma may achieve sitting or standing — once thought impossible.

Comparison with ALS

• Similarities: Both are motor neuron diseases affecting muscle control.
• Differences:
  • Cause: SMA is a single-gene inherited disorder; ALS is mostly sporadic with partial genetic links.
  • Onset: SMA usually in childhood; ALS in adulthood.
  • Neurons affected: ALS affects both upper and lower motor neurons; SMA affects only lower motor neurons.
  • Treatment: SMA has gene-targeted therapies; ALS currently does not.

Latest Developments

• Gene editing (e.g., CRISPR) may one day repair SMN1 mutations.
• Early screening (newborn genetic testing) is already implemented in some countries, enabling timely intervention.

Update: 1/5/2026